Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: What if antipsychotic is discontinued?

International Clinical Psychopharmacology

Volumn 18, Issue 1, 2003, Pages 23-28

  Maina, Giuseppe ^a   Albert, Umberto ^a   Ziero, Simona ^a   Bogetto, Filippo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Antipsychotic; Discontinuation; Obsessive compulsive disorder; SRI

Indexed keywords

CLOMIPRAMINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONFUSION; CONTROLLED STUDY; ERYTHEMA; FEMALE; HUMAN; MALE; MENTAL PATIENT; MUSCLE RIGIDITY; OBSESSIVE COMPULSIVE DISORDER; OUTCOMES RESEARCH; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; RATING SCALE; RELAPSE; RETROSPECTIVE STUDY; SIDE EFFECT; SOMNOLENCE; THERAPY RESISTANCE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; RECURRENCE; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0037239597     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200301000-00004     Document Type: Article

References (37)

1. Albert U, Bergesio C, Pessina E, Maina G, Bogetto F (2002). Management of treatment resistant obsessive-compulsive disorder: algorithms for pharmacotherapy. Panminerva Medica 44:83-91.
2. Atmaca M, Kuloglu M, Tezcan E, Gecici O (2002). Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol 17:115-119.
3. Bogetto F, Bellino S, Vaschetto P, Ziero S (2000). Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res 96:91-98.
4. Bystritsky A, Ackerman A, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S (2001) Augmentation of SSRI response in refractory OCD using adjunctive olanzapine: a placebo-controlled trial. Presented at the Fifth International Obsessive-Compulsive Disorders Conference, Sardinia, Italy, 29 March to 1 April.
5. Dannon PN, Sasson Y, Hirschmann S, Iancu I, Grunhaus LJ, Zohar J (2000). Pindolol augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind placebo controlled trial. Eur Neuropsychopharmacol 10: 165-169.
6. Delgado PL, Goodman WK, Price LH, Heninger GR, Chamey DS (1990). Fluvoxamine/pimozide treatment of concurrent Tourette's and obsessive-compulsive disorder. Br J Psychiatry 157:762-765.
7. Francobandiera G (2001). Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study. Can J Psychiatry 46:356-358.
8. Fux M, Benjamin J, Belmaker RH (1999). Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind, cross-over study. Int J Psychopharmacol 2: 193-195.
9. Grady TA, Pigott TA, L'Eureux F, Hill JL, Bernstein SE, Murphy DL (1993). Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am J Psychiatry 150:818-821.
10. Greist HJ, Chouinard G, DuBoff E, Halarist A, Kim SW, Koran L, et al. (1995). Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 52:289-295.
11. Hollander E, Bienstock CA, Koran LM, Pallanti S, Marazziti D, Rasmussen SA, et al. (2002). Refractory obsessive-compulsive disorder: state-of-the-art treatment. J Clin Psychiatry 63(suppl. 6):20-29.
12. Jacobsen FM (1995). Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry 56:423-429.
13. Jenike MA (1998). Drug treatment of obsessive-compulsive disorders. In: Jenike MA, Baer L, Minichiello WE, (editors): Obsessive-Compulsive Disorders. Practical Management, 3rd edn. St Louis: Mosby; pp. 469-532.
14. Koran LM, Ringold AL, Elliott MA (2000). Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 61:514-517.
15. Marazziti D, Dell'Osso L, Gemignani A, Ciapparelli A, Presta S, Nasso ED, et al. (2001). Citalopram in refractory obsessive-compulsive disorder: an open study. Int Clin Psychopharmacol 16:215-219.
16. March J, Frances A, Carpenter D, Kahn D (1997). The Expert Consensus Guideline Series. Treatment of obsessive-compulsive disorder. J Clin Psychiatry 58(Suppl. 4):1-64.
17. McDougle CJ, Walsh KH (2001). Treatment of refractory obsessive-compulsive disorder. In: Fineberg N, Marazziti D, Stein DJ (editors): Obsessive-Compulsive Disorder: A Practical Guide. London: Martin Dunitz; pp. 135-152.
18. McDougle CJ, Goodman WK, Price LH, Delgado PL, Krystal JH, Charney DS, Heninger GR, et al. (1990). Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 147:652-654.
19. McDougle CJ, Price LH, Goodman WK (1991). A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol 11:175-184.
20. McDougle, Goodman WK, Leckman JF, Holzer JC, Barr LC, McCante-Karz E, et al. (1993). Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 150:647-649.
21. McDougle, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH, et al. (1994). Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 51:302-308.
22. McDougle CJ, Fleischman RL, Epperson CN, Wasylink S, Price LH, et al. (1995). Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J Clin Psychiatry 56:526-528.
23. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH (2000). A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsesswe-compulsive disorder. Arch Gen Psychiatry 57:794-801.
24. Montgomery SA, McIntyre A, Osterheider M, Sarteschi P, Zitterl W, Zohar J, et al. (1993). A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group. Eur Neuropsychopharmacol 3:143-152.
25. Montgomery SA, Kasper S, Stein DJ, Bang Hedegaard K, Lemming OM (2001). Citalopram 20 mg, 40 mg, and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 16:75-86.
26. Mohr N, Vythilingum B, Emsey RA, Stein DJ (2002). Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder. Int Clin Psychopharmacol 17:37-40.
27. Pallanti S, Quercioli L, Paiva RS, Koran LM (1999). Citalopram for treatment-resistant obsessive-compulsive disorder. Eur Psychiatry 14:101-106.
28. Pfanner C, Marazziti D, Dell'Osso L, Presta S, Gemignani A, Milanfranchi A, Cassano GB (2000). Risperidone augmentation in refractory obsessive-compulsive dirorder: an open-label study. Int Clin Psychopharmacol 15: 297-301.
29. Pigott TA, Pato MT, L'Heureux F, Hill JL, Grover GN, Bernstein SE, Murphy DL (1991). A controlled comparison of adjunctive lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 11:242-248.
30. Pigott TA, L'Heureux F, Hill JL, Bihari K, Bernstein SE, Murphy DL (1992). A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 12:11-18.
31. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G (1996). Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol Bull 32:677-682.
32. Saxena S, Wang D, Bystritsky A, Baxter LR, Jr (1996). Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 57:303-306.
33. Simpson HB, Gorfinkle KS, Liebowitz MR (1999). Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial. J Clin Psychiatry 60:584-590.
34. Stein DJ, Bouwer C, Hawkridge S, Emsley RA (1997). Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry 58:119-122.
35. Tollefson G, Rampey A, Potvin J, Jenike MA, Rush AJ, Domingues RA, et al. (1994). A multi-center investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 51:559-567.
36. Weiss EL, Potenza MN, McDougle CJ, Epperson CN (1999). Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J Clin Psychiatry 60:524-527.
37. Wheadon DE, Bushnell WD, Steiner M (1993). A fixed dose comparison of 20, 40 or 60 mg paroxetine to placebo in the treatment of obsessive-compulsive disorder. In: Abstracts of Panels and Posters presented at the Annual Meeting of the American College of Neuropsychopharmacology. Nashville, TN: Vanderbilt University.